The North America Lymphoma Therapeutics Market would witness market growth of 7.3% CAGR during the forecast period (2023-2029).
The primary element that is projected to be the primary driver of growth in the lymphoma treatment market is an increase in research and development activities among key companies for the development of lymphoma therapies with fewer side effects. This is the primary driver anticipated to foster growth in the lymphoma treatment market. On the other hand, new possibilities will likely arise during the projected period due to the public's growing awareness of lymphoma and the various treatment choices available for the disease.
On the other hand, it is anticipated that the increasing incidence of non-Hodgkin lymphoma, as well as the rise in awareness and concern over the accessibility of a variety of treatment choices for lymphoma, would present lucrative chances for the expansion of the lymphoma therapeutics market throughout the course of the forecast period.
An unprecedented rise in the market for lymphoma therapeutics is anticipated to be driven by substantial unmet clinical needs connected to the illness as well as the launch of new products. In addition, the prospective drug pipeline, shifting treatment trends, increasing prevalence of lymphoma, higher finance from several countries, increased awareness, and faster approvals supplied by regulatory bodies are all factors driving the revenue growth of the market.
In the United States, investments have reduced the incidence of new cancer cases and cancer-related fatalities over the past few decades. Aligned with this trend, the overall count of cancer survivors within the United States has increased from 7 million in 1992 to surpassing fifteen million in 2016, with an estimated surge to exceed 26 million by 2040. In addition, as a result of advancements in cancer detection, diagnosis, and patient care, people are leading longer and healthier lives than ever before. Hence, the constant effort by the government to decrease the deaths from various types of cancer like lymphoma and create effective therapeutics measures is expected to increase the development and utilization of lymphoma therapeutics and therefore aid the market to grow in the region.
The US market dominated the North America Lymphoma Therapeutics Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $6,819.7 million by 2029. The Canada market is poised to grow at a CAGR of 9.7% during (2023 - 2029). Additionally, The Mexico market would witness a CAGR of 8.7% during (2023 - 2029).
Based on Treatment Type, the market is segmented into Immune Therapy, Target Therapy, Chemotherapy, and Radiation Therapy. Based on Disease Type, the market is segmented into Non-Hodgkin Lymphoma, and Hodgkin Lymphoma. Based on Route of Administration, the market is segmented into Injectable, and Oral Route. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Worldwide Lymphoma Therapeutics Market is Projected to reach USD 24.9 Billion by 2029, at a CAGR of 7.8%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AstraZeneca PLC, Bayer AG, Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Gilead Sciences, Inc., Seagen, Inc., Teva Pharmaceutical Industries Ltd., Pfizer, Inc. and Eli Lilly And Company.
Scope of the Study
Market Segments Covered in the Report:
By Treatment Type
- Immune Therapy
- Target Therapy
- Chemotherapy
- Radiation Therapy
By Disease Type
- Non-Hodgkin Lymphoma
- Hodgkin Lymphoma
By Route of Administration
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- AstraZeneca PLC
- Bayer AG
- Bristol Myers Squibb Company
- F.Hoffmann-La Roche Ltd.
- Johnson & Johnson
- Gilead Sciences, Inc.
- Seagen, Inc.
- Teva Pharmaceutical Industries Ltd.
- Pfizer, Inc.
- Eli Lilly And Company
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Lymphoma Therapeutics Market, by Treatment Type
1.4.2 North America Lymphoma Therapeutics Market, by Disease Type
1.4.3 North America Lymphoma Therapeutics Market, by Route of Administration
1.4.4 North America Lymphoma Therapeutics Market, by Distribution Channel
1.4.5 North America Lymphoma Therapeutics Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition & scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
Chapter 4. North America Lymphoma Therapeutics Market by Treatment Type
4.1 North America Immune Therapy Market by Country
4.2 North America Target Therapy Market by Country
4.3 North America Chemotherapy Market by Country
4.4 North America Radiation Therapy Market by Country
Chapter 5. North America Lymphoma Therapeutics Market by Disease Type
5.1 North America Non-Hodgkin Lymphoma Market by Country
5.2 North America Hodgkin Lymphoma Market by Country
Chapter 6. North America Lymphoma Therapeutics Market by Route of Administration
6.1 North America Injectable Market by Country
6.2 North America Oral Route Market by Country
Chapter 7. North America Lymphoma Therapeutics Market by Distribution Channel
7.1 North America Hospital Pharmacies Market by Country
7.2 North America Retail Pharmacies Market by Country
7.3 North America Others Market by Country
Chapter 8. North America Lymphoma Therapeutics Market by Country
8.1 US Lymphoma Therapeutics Market
8.1.1 US Lymphoma Therapeutics Market by Treatment Type
8.1.2 US Lymphoma Therapeutics Market by Disease Type
8.1.3 US Lymphoma Therapeutics Market by Route of Administration
8.1.4 US Lymphoma Therapeutics Market by Distribution Channel
8.2 Canada Lymphoma Therapeutics Market
8.2.1 Canada Lymphoma Therapeutics Market by Treatment Type
8.2.2 Canada Lymphoma Therapeutics Market by Disease Type
8.2.3 Canada Lymphoma Therapeutics Market by Route of Administration
8.2.4 Canada Lymphoma Therapeutics Market by Distribution Channel
8.3 Mexico Lymphoma Therapeutics Market
8.3.1 Mexico Lymphoma Therapeutics Market by Treatment Type
8.3.2 Mexico Lymphoma Therapeutics Market by Disease Type
8.3.3 Mexico Lymphoma Therapeutics Market by Route of Administration
8.3.4 Mexico Lymphoma Therapeutics Market by Distribution Channel
8.4 Rest of North America Lymphoma Therapeutics Market
8.4.1 Rest of North America Lymphoma Therapeutics Market by Treatment Type
8.4.2 Rest of North America Lymphoma Therapeutics Market by Disease Type
8.4.3 Rest of North America Lymphoma Therapeutics Market by Route of Administration
8.4.4 Rest of North America Lymphoma Therapeutics Market by Distribution Channel
Chapter 9. Company Profiles
9.1 Bayer AG
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Segmental and Regional Analysis
9.1.4 Research & Development Expense
9.1.5 Recent strategies and developments:
9.1.5.1 Approvals and Trials:
9.1.6 SWOT Analysis
9.2 Johnson & Johnson
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Segmental &Regional Analysis
9.2.4 Research & Development Expenses
9.2.5 SWOT Analysis
9.3 Gilead Sciences, Inc.
9.3.1 Company overview
9.3.2 Financial Analysis
9.3.3 Research & Development Expenses
9.3.4 Recent strategies and developments:
9.3.4.1 Partnerships, Collaborations, and Agreements:
9.3.4.2 Acquisition and Mergers:
9.3.4.3 Approvals and Trials:
9.4 Bristol Myers Squibb Company
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Regional Analysis
9.4.4 Research & Development Expenses
9.4.5 Recent strategies and developments:
9.4.5.1 Acquisition and Mergers:
9.4.5.2 Approvals and Trials:
9.5 Pfizer, Inc.
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Regional & Segmental Analysis
9.5.4 Research & Development Expense
9.5.5 Recent strategies and developments:
9.5.5.1 Acquisition and Mergers:
9.5.5.2 Approvals and Trials:
9.6 AstraZeneca PLC
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Regional Analysis
9.6.4 Research & Development Expenses
9.6.5 Recent strategies and developments:
9.6.5.1 Partnerships, Collaborations, and Agreements:
9.6.5.2 Acquisition and Mergers:
9.6.5.3 Approvals and Trials:
9.7 Teva Pharmaceutical Industries Ltd.
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Regional Analysis
9.7.4 Research & Development Expenses
9.7.5 Recent strategies and developments:
9.7.5.1 Partnerships, Collaborations, and Agreements:
9.7.5.2 Product Launches and Product Expansions:
9.8 Eli Lilly And Company
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Regional Analysis
9.8.4 Research & Development Expenses
9.8.5 Recent strategies and developments:
9.8.5.1 Acquisition and Mergers:
9.8.5.2 Approvals and Trials:
9.9 Seagen, Inc.
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Research & Development Expenses
9.9.4 Recent strategies and developments:
9.9.4.1 Approvals and Trials:
9.10. F. Hoffmann-La Roche Ltd.
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Segmental and Regional Analysis
9.10.4 Research & Development Expense
TABLE 1 North America Lymphoma Therapeutics Market, 2019 - 2022, USD Million
TABLE 2 North America Lymphoma Therapeutics Market, 2023 - 2029, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Lymphoma Therapeutics Market
TABLE 4 Product Launches And Product Expansions– Lymphoma Therapeutics Market
TABLE 5 Acquisition and Mergers– Lymphoma Therapeutics Market
TABLE 6 Approvals and trials – Lymphoma Therapeutics Market
TABLE 7 North America Lymphoma Therapeutics Market by Treatment Type, 2019 - 2022, USD Million
TABLE 8 North America Lymphoma Therapeutics Market by Treatment Type, 2023 - 2029, USD Million
TABLE 9 North America Immune Therapy Market by Country, 2019 - 2022, USD Million
TABLE 10 North America Immune Therapy Market by Country, 2023 - 2029, USD Million
TABLE 11 North America Target Therapy Market by Country, 2019 - 2022, USD Million
TABLE 12 North America Target Therapy Market by Country, 2023 - 2029, USD Million
TABLE 13 North America Chemotherapy Market by Country, 2019 - 2022, USD Million
TABLE 14 North America Chemotherapy Market by Country, 2023 - 2029, USD Million
TABLE 15 North America Radiation Therapy Market by Country, 2019 - 2022, USD Million
TABLE 16 North America Radiation Therapy Market by Country, 2023 - 2029, USD Million
TABLE 17 North America Lymphoma Therapeutics Market by Disease Type, 2019 - 2022, USD Million
TABLE 18 North America Lymphoma Therapeutics Market by Disease Type, 2023 - 2029, USD Million
TABLE 19 North America Non-Hodgkin Lymphoma Market by Country, 2019 - 2022, USD Million
TABLE 20 North America Non-Hodgkin Lymphoma Market by Country, 2023 - 2029, USD Million
TABLE 21 North America Hodgkin Lymphoma Market by Country, 2019 - 2022, USD Million
TABLE 22 North America Hodgkin Lymphoma Market by Country, 2023 - 2029, USD Million
TABLE 23 North America Lymphoma Therapeutics Market by Route of Administration, 2019 - 2022, USD Million
TABLE 24 North America Lymphoma Therapeutics Market by Route of Administration, 2023 - 2029, USD Million
TABLE 25 North America Injectable Market by Country, 2019 - 2022, USD Million
TABLE 26 North America Injectable Market by Country, 2023 - 2029, USD Million
TABLE 27 North America Oral Route Market by Country, 2019 - 2022, USD Million
TABLE 28 North America Oral Route Market by Country, 2023 - 2029, USD Million
TABLE 29 North America Lymphoma Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 30 North America Lymphoma Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 31 North America Hospital Pharmacies Market by Country, 2019 - 2022, USD Million
TABLE 32 North America Hospital Pharmacies Market by Country, 2023 - 2029, USD Million
TABLE 33 North America Retail Pharmacies Market by Country, 2019 - 2022, USD Million
TABLE 34 North America Retail Pharmacies Market by Country, 2023 - 2029, USD Million
TABLE 35 North America Others Market by Country, 2019 - 2022, USD Million
TABLE 36 North America Others Market by Country, 2023 - 2029, USD Million
TABLE 37 North America Lymphoma Therapeutics Market by Country, 2019 - 2022, USD Million
TABLE 38 North America Lymphoma Therapeutics Market by Country, 2023 - 2029, USD Million
TABLE 39 US Lymphoma Therapeutics Market, 2019 - 2022, USD Million
TABLE 40 US Lymphoma Therapeutics Market, 2023 - 2029, USD Million
TABLE 41 US Lymphoma Therapeutics Market by Treatment Type, 2019 - 2022, USD Million
TABLE 42 US Lymphoma Therapeutics Market by Treatment Type, 2023 - 2029, USD Million
TABLE 43 US Lymphoma Therapeutics Market by Disease Type, 2019 - 2022, USD Million
TABLE 44 US Lymphoma Therapeutics Market by Disease Type, 2023 - 2029, USD Million
TABLE 45 US Lymphoma Therapeutics Market by Route of Administration, 2019 - 2022, USD Million
TABLE 46 US Lymphoma Therapeutics Market by Route of Administration, 2023 - 2029, USD Million
TABLE 47 US Lymphoma Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 48 US Lymphoma Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 49 Canada Lymphoma Therapeutics Market, 2019 - 2022, USD Million
TABLE 50 Canada Lymphoma Therapeutics Market, 2023 - 2029, USD Million
TABLE 51 Canada Lymphoma Therapeutics Market by Treatment Type, 2019 - 2022, USD Million
TABLE 52 Canada Lymphoma Therapeutics Market by Treatment Type, 2023 - 2029, USD Million
TABLE 53 Canada Lymphoma Therapeutics Market by Disease Type, 2019 - 2022, USD Million
TABLE 54 Canada Lymphoma Therapeutics Market by Disease Type, 2023 - 2029, USD Million
TABLE 55 Canada Lymphoma Therapeutics Market by Route of Administration, 2019 - 2022, USD Million
TABLE 56 Canada Lymphoma Therapeutics Market by Route of Administration, 2023 - 2029, USD Million
TABLE 57 Canada Lymphoma Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 58 Canada Lymphoma Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 59 Mexico Lymphoma Therapeutics Market, 2019 - 2022, USD Million
TABLE 60 Mexico Lymphoma Therapeutics Market, 2023 - 2029, USD Million
TABLE 61 Mexico Lymphoma Therapeutics Market by Treatment Type, 2019 - 2022, USD Million
TABLE 62 Mexico Lymphoma Therapeutics Market by Treatment Type, 2023 - 2029, USD Million
TABLE 63 Mexico Lymphoma Therapeutics Market by Disease Type, 2019 - 2022, USD Million
TABLE 64 Mexico Lymphoma Therapeutics Market by Disease Type, 2023 - 2029, USD Million
TABLE 65 Mexico Lymphoma Therapeutics Market by Route of Administration, 2019 - 2022, USD Million
TABLE 66 Mexico Lymphoma Therapeutics Market by Route of Administration, 2023 - 2029, USD Million
TABLE 67 Mexico Lymphoma Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 68 Mexico Lymphoma Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 69 Rest of North America Lymphoma Therapeutics Market, 2019 - 2022, USD Million
TABLE 70 Rest of North America Lymphoma Therapeutics Market, 2023 - 2029, USD Million
TABLE 71 Rest of North America Lymphoma Therapeutics Market by Treatment Type, 2019 - 2022, USD Million
TABLE 72 Rest of North America Lymphoma Therapeutics Market by Treatment Type, 2023 - 2029, USD Million
TABLE 73 Rest of North America Lymphoma Therapeutics Market by Disease Type, 2019 - 2022, USD Million
TABLE 74 Rest of North America Lymphoma Therapeutics Market by Disease Type, 2023 - 2029, USD Million
TABLE 75 Rest of North America Lymphoma Therapeutics Market by Route of Administration, 2019 - 2022, USD Million
TABLE 76 Rest of North America Lymphoma Therapeutics Market by Route of Administration, 2023 - 2029, USD Million
TABLE 77 Rest of North America Lymphoma Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 78 Rest of North America Lymphoma Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 79 Key Information – Bayer AG
TABLE 80 Key information –Johnson & Johnson
TABLE 81 Key Information – Gilead Sciences, Inc.
TABLE 82 Key Information – Bristol Myers Squibb Company
TABLE 83 Key Information – Pfizer, Inc.
TABLE 84 KEY INFORMATION – AstraZeneca PLC
TABLE 85 Key Information – Teva Pharmaceuticals Industries Ltd.
TABLE 86 Key Information – Eli Lilly And Company
TABLE 87 Key Information – Seagen Inc.
TABLE 88 KEY INFORMATION – F. Hoffmann-La Roche Ltd.
List of Figures
FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Key Leading Strategies: Percentage Distribution (2019-2023)
FIG 4 Swot analysis: bayer ag
FIG 5 SWOT analysis: Johnson & Johnson
FIG 6 Recent strategies and developments: Gilead Sciences, Inc.
FIG 7 Recent strategies and developments: Bristol Myers Squibb Company
FIG 8 Recent strategies and developments: Pfizer, Inc.
FIG 9 Recent strategies and developments: AstraZeneca PLC